Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 8/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL611634 | 0.95 | TSPO (0.65) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL611533 | 0.91 | TSPO (0.71) | TSPO | |
| SCHEMBL612350 | 0.91 | TSPO (0.56) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL610226 | 0.90 | TSPO (0.59) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL612244 | 0.88 | TSPO (0.58) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL609505 | 0.88 | TSPO (0.58) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL611949 | 0.88 | TSPO (0.61) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL612319 | 0.88 | GABRA2 (0.56) | TSPO | |
| SCHEMBL611953 | 0.85 | TSPO (0.57) | TSPONR1I2ABCB11ALBADORA3 | |
| SCHEMBL612773 | 0.85 | TSPO (0.65) | TSPONR1I2ABCB11ALBADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040979-A1 | IMIDAZO[1,2-B]PYRIDAZINES, PROCESSES, USES, INTERMEDIATES AND COMPOSITIONS | FALCO JOSE LUIS (ES) | 2012-02-16 | — | — | US | claimed |
| EP-2010536-B1 | IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | FERRER INT (ES) | 2010-06-16 | — | — | EP | claimed |
| US-20090176788-A1 | Imidazo[1,2-B]Pyridazines, Processes, Uses, Intermediates and Compositions | FERRER INTERNACIONAL, S.A. (ES) | 2009-07-09 | — | — | US | claimed |
| EP-2010536-A1 | IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | Ferrer Internacional, S.A. (ES) | 2009-01-07 | — | — | EP | claimed |
| EP-1845098-A1 | Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands | FERRER INTERNACIONAL, S.A. (ES) | 2007-10-17 | — | — | EP | claimed |
| WO-2007110437-A1 | IMIDAZO [1, 2-B] PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | FERRER INTERNACIONAL, S.A. (ES) | 2007-10-04 | — | — | WO | claimed |
| US-8993562-B2 | Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2015-03-31 | — | — | US | disclosed |
| US-8153789-B2 | Imidazo[1,2-b]pyridazines, processes, uses, intermediates and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2012-04-10 | — | — | US | disclosed |
| US-20120040979-A1 | IMIDAZO[1,2-B]PYRIDAZINES, PROCESSES, USES, INTERMEDIATES AND COMPOSITIONS | FALCO JOSE LUIS (ES) | 2012-02-16 | — | — | US | disclosed |
| EP-2010536-B1 | IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | FERRER INT (ES) | 2010-06-16 | — | — | EP | disclosed |
| US-20090176788-A1 | Imidazo[1,2-B]Pyridazines, Processes, Uses, Intermediates and Compositions | FERRER INTERNACIONAL, S.A. (ES) | 2009-07-09 | — | — | US | disclosed |
| EP-2010536-A1 | IMIDAZO [1, 2-B]PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | Ferrer Internacional, S.A. (ES) | 2009-01-07 | — | — | EP | disclosed |
| EP-1845098-A1 | Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands | FERRER INTERNACIONAL, S.A. (ES) | 2007-10-17 | — | — | EP | disclosed |
| WO-2007110437-A1 | IMIDAZO [1, 2-B] PYRIDAZINES, THEIR PROCESSES OF PREPARATION AND THEIR USE AS GABA RECEPTOR LIGANDS | FERRER INTERNACIONAL, S.A. (ES) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176788-A1 | Imidazo[1,2-B]Pyridazines, Processes, Uses, Intermediates and Compositions | GABRA5, GABRA1, GABRA2 | TSPO 140/4885NR1I2 24/4885ABCB11 2216/4885 |
| US-20120040979-A1 | IMIDAZO[1,2-B]PYRIDAZINES, PROCESSES, USES, INTERMEDIATES AND COMPOSITIONS | GABRA5, GABRA1, GABRA2 | TSPO 140/4885NR1I2 24/4885ABCB11 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.